NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 1st July 2025

**Location:** Via Zoom and London office

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Richard Ballerand Present for all items
4. Dr Ian Bernstein Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Patrick De Barr Items 5.1. to 5.2.2
7. Dr Steve Edwards Items 5.1. to 5.2.2
8. Victoria Houghton Present for all items
9. Vageesh Jain Present for all items
10. Dr Fiona MacPherson-Smith Items 1.1 to 4.2.2
11. Dr Youssof Oskrochi Items 5.1. to 5.2.2
12. Dr Zoe Philps Present for all items
13. Hugo Pedder Present for all items
14. Becky Pennington Present for all items
15. Dominic Pivonka Present for all items
16. Dr Ravi Ramessur Present for all items
17. Min Ven Teo Present for all items
18. Jaqueline Tomlinson Present for all items
19. Matthew Walton Present for all items

NICE staff (key players) present

Ian Watson, Associate Director Items 1.1 to 4.2.2

Jennifer Upton, Project Manager Items 1.1 to 4.2.2

Yelan Guo, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Sharlene Ting, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Emily Crowe, Associate Director Items 5.1 to 5.2.2

Jeremy Powell, Project Manager Items 5.1 to 5.2.2

Alan Moore, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Luke Cowie, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Tracey Jhita, BMJ Items 1.1 to 4.2.2

Vicky Wakefield, BMJ Items 1.1 to 4.2.2

Daniel Gallacher, Birmingham Centre for Evidence and Implementation Science

Items 5.1 to 5.2.2

Mehdi Yusefi, Birmingham Centre for Evidence and Implementation Science

Items 5.1 to 5.2.2

Clinical, Patient & NHS England experts present

Dr John McGrane, Clinical expert, Consultant oncologist, Royal Cornwall Hospital – nominated by GlaxoSmithKline Items 1.1 to 4.1.3

Dr Andrew Clamp, Clinical expert, Consultant and Honorary Senior Lecturer in Medical Oncology, The Christe NHS Foundation Trust, nominated by GlaxoSmithKline

Items 1.1 to 4.1.3

Jane McCarthy-Penman, Patient expert, Company secretary, nominated by Peaches Womb Cancer Trust Items 1.1 to 4.1.3

Grace Teeling, Patient expert, Policy Lead, Peaches Womb Cancer Trust, nominated by Peaches Womb Cancer Trust Items 1.1 to 4.1.3

James Richardson, CDF representative Items 1.1 to 4.1.3

Items 5.1 to 5.1.3

Dr Sunil Iyengar, Clinical Expert, Consultant Haematologist nominated by Gilead Sciences

Items 5.1 to 5.1.3

Professor Andrew Davies, Clinical Expert, Professor of Haematological Oncology and Honorary Consultant nominated by Gilead Sciences Items 5.1 to 5.1.3

Susannah Wood, Patient Expert, nominated by Lymphoma Action

Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Radha Todd, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Elizabeth Adeyeye, Craig Buckley and Mohamad Farhat.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 3rd June.

### Appraisal of Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from GlaxoSmithKline.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11503).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Richard Ballerand/James Fotheringham (lay), Ravi (clinical) Ramessur and Hugo Pedder (cost).
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11503>.

### Appraisal of Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

* 1. Part 1 – Open session
     1. The chair, Radha Todd, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Gilead Sciences Ltd.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11545).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Richard Ballerand (lay), Patrick de Barr (clinical) and James Fotheringham (cost).
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11545>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 5th August and will start promptly at 9am.